Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Abeona Therapeutics

Tracked across 3 events · 18 articles · First seen Apr 02, 2026 · Last active Sep 03, 2026

Sentiment
-7
Attention
4
Events
3
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 20
Business
Impact: Abeona expands commercial footprint for ZEVASKYN by adding a large EB center as a QTC, potentially boosting sales.
Jul 21, 2026 · 6 articles
2 -40
Regulatory
Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (Nasdaq: ABEO) concerning potential securities fraud or other unlawful business practices by the company and certain officers and/or directors. The investigation follows…
Impact: Abeona is the subject of the investigation. The company's stock dropped 14.95% after disclosing a revenue recognition shortfall for ZEVASKYN, and it now faces potential securities fraud claims.
Aug 27, 2026 · 6 articles
4 0
Regulatory
Impact: Abeona Therapeutics originally developed UX111 before transferring it to Ultragenyx for further development.
Apr 02, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Abeona Therapeutics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.